

## Binding Commitments Received for a ~\$4 Million Placement

### Highlights:

- **Binding commitments for a ~\$4 million Placement with support from existing and new institutional, professional and sophisticated investors**
- **Subject to shareholder approval, all directors of the Company have elected to participate into this Placement (for a total of ~\$250,000)**
- **Funds raised under the Placement will be applied towards advancing NTI164 non-clinical toxicology and registration-enabling clinical programs, progressing regulatory submissions, and supporting general working capital.**

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, is pleased to announce it has received binding commitments from investors totalling ~\$4 Million ("Placement") for the issue of 285,976,909 new fully paid ordinary shares ("New Shares").

**Dr Anthony Filippis, Managing Director and CEO of Neurotech said** "On behalf of the Board of Directors of Neurotech, we thank investors for their strong support of the Placement, and welcome our new investors. As we move into 2026, we are focused on deploying these funds to advance the development of NTI164 for paediatric neurological disorders. The commitment of both existing and new investors provides a solid foundation as we pursue our mission to deliver innovative treatment options for patients and families affected by these challenging conditions."

### Details of Placement

The Placement will be conducted, as follows:

- 246,691,195 shares to be issued to non-related institutional, professional and sophisticated investors on or around 23 December 2025 (for a total of ~\$3,453,676), using the Company's existing issue capacity set out below:
  - o 141,729,003 New Shares will be issued under the Company's issue capacity pursuant to ASX Listing Rule 7.1.
  - o 104,962,192 New Shares issued under the Company's placement capacity pursuant to ASX Listing Rule 7.1A.
- Subject to shareholder approval:
  - o 17,857,142 shares are intended to be issued to directors of the Company for a total participation of ~\$250,000, as follows:
    - Mark Davies: participation of ~\$100,000 for the issue of 7,142,858 shares;
    - Anthony Filippis: participation of ~\$50,000 for the issue of 3,571,428 shares;
    - Gerald Quigley: participation of ~\$50,000 for the issue of 3,571,428 shares; and
    - Robert Maxwell Johnston: participation of ~\$50,000 for the issue of 3,571,428 shares.
  - o A further 21,428,572 shares are intended to be issued to non-related party investors for a participation of ~\$300,000.

The issue price under the Placement is \$0.014 per New Share, representing a 23.8% discount to the 15 day VWAP of \$0.0184.

Funds raised under the placement will be applied towards advancing NTI164 non-clinical toxicology and registration-enabling clinical programs, progressing regulatory submissions, and supporting general working capital.

Taylor Collison Limited acted as Lead Manager for the Placement and will receive a 2% management fee and 4% selling fee on the gross Placement proceeds.

Refer to the Appendices 3B lodged by the Company today for further disclosures in connection with the Placement.

### **Authority**

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via [info@neurotechinternational.com](mailto:info@neurotechinternational.com)

### **About Neurotech**

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.